SIPP_Ulcer

The chart shows the growth of an initial investment of £10,000 in SIPP_Ulcer, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Sep 27, 2019, SIPP_Ulcer's average daily return is +0.06%, while the average monthly return is +1.19%. At this rate, your investment would double in approximately 4.9 years.

Historically, 63% of months were positive and 38% were negative. The best month was Apr 2020 with a return of +9.8%, while the worst month was Mar 2026 at -8.4%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 3 months.

On a daily basis, SIPP_Ulcer closed higher 53% of trading days. The best single day was Mar 24, 2020 with a return of +5.1%, while the worst single day was Mar 12, 2020 at -6.3%.

SIPP_Ulcer has an annualized alpha of 11.97%, beta of 0.26, and R² of 0.14 versus S&P 500 Index. Calculated based on daily prices since September 27, 2019.

• This portfolio participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (59.65%) than losses (19.42%) — typical of diversified or defensive assets.
• Beta of 0.26 may look defensive, but with R² of 0.14 this portfolio is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this portfolio's risk.
• R² of 0.14 means this portfolio moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

SIPP_Ulcer has an expense ratio of 0.22%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

SIPP_Ulcer ranks 94 for risk / return — in the top 94% of portfolios on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

SIPP_Ulcer Sharpe ratios as of Apr 4, 2026 (values are recalculated daily):

• 1-Year: 2.64
• 5-Year: 1.33
• All Time: 1.10

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 0.99 to 1.69, this portfolio's current Sharpe ratio is in the top 25%. This signifies superior risk-adjusted performance, meaning the portfolio is delivering strong returns for the level of risk taken compared to most others.

The chart below shows the rolling Sharpe ratio of SIPP_Ulcer compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the SIPP_Ulcer. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the SIPP_Ulcer was 19.27%, occurring on Mar 16, 2020. Recovery took 44 trading sessions.

The current SIPP_Ulcer drawdown is 7.36%.

The chart below shows the rolling one-month volatility.